Previous studies have also identified a crosstalk between Nucleolin, ErbB1, and Ras proteins, and demonstrated that treatment with a combination of FTS (which inhibits the Ras proteins) and GroA (AS1411, which targets cell surface Nucleolin) has a stronger inhibitory effect on several types of cancer cells, i.e., colon cancer cells (DLD-1 and HCT-116), prostate cancer cells (DU-145 and PC-3) and glioblastoma cells (U-87), leading to the inhibition of cell growth and anchorage independent growth [27,28,29]. Here, CXCL1 is linked to prostate cancer.